# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Facioscapulohumeral muscular dystrophy

FSHDLandouzy-Dejerine Muscular Dystrophy
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-9 of 9 results.
The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
Status: Recruiting
Last Changed: Jul 02, 2019
First Received: Jun 28, 2019
Disease(s): Facioscapulohumeral Muscular Dystrophy
Intervention(s): Patient Registry
Locations: John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, United Kingdom
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Status: Recruiting
Last Changed: Oct 02, 2019
First Received: Jul 01, 2019
Disease(s): Facioscapulohumeral Muscular Dystrophy (FSHD)
Intervention(s): Losmapimod, Placebo oral tablet
Locations: University of California Irvine, Irvine, California, United States
University of California Los Angeles (UCLA), Los Angeles, California, United States
University of Florida, Gainesville, Florida, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Kennedy Krieger Institute, Baltimore, Maryland, United States
... and 16 other locations.
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Jul 01, 2019
Disease(s): Facioscapulohumeral Muscular Dystrophy 1
Intervention(s): Losmapimod
Locations: Radboud University Medical Center, Nijmegen, Netherlands
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Status: Recruiting
Last Changed: Feb 06, 2019
First Received: Mar 08, 2018
Disease(s): Facioscapulohumeral Muscular Dystrophy
Intervention(s): FSHD-specific functional rating scale, Electrical Impedance Myography
Locations: University of California Los Angeles, Los Angeles, California, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Kennedy Krieger Institute, Baltimore, Maryland, United States
University of Rochester Medical Center, Rochester, New York, United States
The Ohio State University, Columbus, Ohio, United States
... and 4 other locations.
Study of Testosterone and rHGH in FSHD
Status: Recruiting
Last Changed: Mar 06, 2019
First Received: Apr 21, 2017
Disease(s): Facioscapulohumeral Muscular Dystrophy
Intervention(s): Testosterone Enanthate, Somatropin
Locations: University of Rochester, Rochester, New York, United States
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Status: Recruiting
Last Changed: Oct 04, 2018
First Received: Apr 30, 2004
Disease(s): Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Locations: University of Rochester Medical Center, Department of Neurology, Rochester, New York, United States
Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD
Status: Recruiting
Last Changed: Aug 26, 2019
First Received: Oct 28, 2016
Disease(s): Facio-Scapulo-Humeral Dystrophy, FSHD2, FSHD1
Intervention(s): Creatine Monohydrate, Placebo
Locations: The Royal Children's Hospital, Melbourne, Victoria, Australia
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Aug 29, 2013
Disease(s): All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Locations: Sanguine Biosciences, Los Angeles, California, United States
Clinical Trial Readiness Network FSHD France: Prospective 18 Months MRI Study
Status: Not yet recruiting
Last Changed: Jul 30, 2019
First Received: Jul 30, 2019
Disease(s): Muscular Dystrophy, Facioscapulohumeral
Intervention(s): Validation of FSHD in French as COA